• 1
    De Geest S, Dobbels F, Fluri C, Paris W, Troosters T. Adherence to the therapeutic regimen in heart, lung, and heart-lung transplant recipients. J Cardiovasc Nurs 2005; 20: 88.
  • 2
    Laederach-Hofmann K, Bunzel B. Noncompliance in organ transplant recipients: a literature review. Gen Hosp Psychiatry 2000; 22: 412.
  • 3
    Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16: 1839.
  • 4
    Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296.
  • 5
    Trunecka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant 2010; 10: 2313.
  • 6
    Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 1211.
  • 7
    Undre NA, for the Tacrolimus Modified Relase Liver Study Group. Use of once daily modified release tacrolimus regimen in de novo liver transplant recipients. Am J Transplant 2005; 5: 374, Abs. 859.
  • 8
    Demetris A, Adams D, Bellamy C, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology 2000; 31: 792.
  • 9
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206.
  • 10
    Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000; 23: 1108.
  • 11
    Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766.
  • 12
    De Geest S, Abraham I, Dunbar-Jacob J. Measuring transplant patients’ compliance with immunosuppressive therapy. West J Nurs Res 1996; 18: 595.
  • 13
    Dobbels F, Berben L, De Geest S, et al. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation 2010; 90: 205.
  • 14
    Amico KR, Fisher WA, Cornman DH, et al. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr 2006; 42: 455.
  • 15
    Hardinger KL, Park JM, Schnitzler MA, Koch MJ, Miller BW, Brennan DC. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. Am J Transplant 2004; 4: 621.
  • 16
    Bekersky I, Dressler D, Mekki QA. Effect of low- and high-fat meals on tacrolimus absorption following 5 mg single oral doses to healthy human subjects. J Clin Pharmacol 2001; 41: 176.
  • 17
    Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol 2001; 41: 289.
  • 18
    Ekong UD, Bhagat H, Alonso EM. Once daily calcineurin inhibitor monotherapy in pediatric liver transplantation. Am J Transplant 2010; 10: 883.
  • 19
    Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623.
  • 20
    Ishibashi M, Yoshida K, Ozono S, et al. Experimental study of tacrolimus immunosuppression on the mode of administration: efficacy of constant intravenous infusion avoiding C(max). Transplant Proc 2001; 33: 559.
  • 21
    Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
  • 22
    Tinti F, Mecule A, Poli L, et al. Improvement of graft function and cardiovascular risk factors after once-daily tacrolimus conversion in stable kidney transplant patients. Transplantation 2010; 90: 635, Abs. 13.
  • 23
    Zaltzman JS, Ferguson R. A comparison of effects of short-term maintenance dose exposure of Advagraf and Neoral on renal perfusion and function in healthy volunteers. Am J Transplant 2010; 10: 522, Abs. 1702.
  • 24
    Merli M, Di Menna S, Giusto M, et al. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient. Transplant Proc 2010; 42: 1322.
  • 25
    Comuzzi C, Lorenzin D, Rossetto A, et al. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients. Transplant Proc 2010; 42: 1320.
  • 26
    Marin-Gomez LM, Gomez-Bravo MA, Alamo-Martinez JA, et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. Transplant Proc 2009; 41: 2184.
  • 27
    Florman S, Alloway R, Kalayoglu M, et al. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation 2007; 83: 1639.
  • 28
    Dobbels F, Vanhaecke J, Desmyttere A, Dupont L, Nevens F, De Geest S. Prevalence and correlates of self-reported pretransplant nonadherence with medication in heart, liver, and lung transplant candidates. Transplantation 2005; 79: 1588.
  • 29
    Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007; 57: 81.
  • 30
    Cramer JA, Scheyer RD, Mattson RH. Compliance declines between clinic visits. Arch Intern Med 1990; 150: 1509.
  • 31
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487.
  • 32
    Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881.
  • 33
    Rand C, Bilderback A, Schiller K, Edelman JM, Hustad CM, Zeiger RS. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol 2007; 119: 916.
  • 34
    Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15: e22.